← Back to Clinical Trials
Recruiting NCT06018792

NCT06018792 Molecular Culture for the Diagnosis of Pediatric Sepsis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06018792
Status Recruiting
Phase
Sponsor Jip Groen
Condition Sepsis
Study Type OBSERVATIONAL
Enrollment 1,835 participants
Start Date 2024-03-10
Primary Completion 2026-11-01

Eligibility & Interventions

Sex All sexes
Min Age 0 Years
Max Age 18 Years
Study Type OBSERVATIONAL
Interventions
Molecular Culture

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,835 participants in total. It began in 2024-03-10 with a primary completion date of 2026-11-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Babies and children have an increased risk of getting an infection with a bacteria in the bloodstream (sepsis). It is often difficult for the doctor to determine whether a child has an infection of the bloodstream, because the symptoms are often unclear and can also occur in children who are not sick. To determine whether there is an infection, a little blood is currently taken for a blood test (the blood culture) to investigate whether there is a bacteria in the blood. However, it often takes at least 36 hours before the results of this blood culture are available. That is why antibiotics are usually started immediately to treat the possible infection. However, it often turns out that the blood culture is negative after 36 hours, which means that no bacteria have been found in the blood. Usually the antibiotics are then stopped because it turns out that there was no infection at all. There is currently no good test that can predict whether (newborn) children have an infection or not. That is why too many children are currently wrongly receiving antibiotics. These antibiotics can damage the healthy bacteria in the intestines. There are many billions of 'beneficial bacteria' in the intestine. These play an important role in the digestion of food and protect against external infections. Antibiotics aim to kill bacteria that cause inflammation or infection. Unfortunately, antibiotics also kill some of these beneficial bacteria. In addition, unnecessary use of antibiotics contributes to antibiotic resistance. The aim of this research is to investigate whether Molecular Culture, a PCR based test that can identify bacterial pathogens in bodily fluids within 4 hours, has greater accuracy than traditional culturing techniques for bacteria in blood. If proven, this could lead to faster identification or exclusion of sepsis in children.

Eligibility Criteria

Inclusion Criteria: * Undergoing collection of blood for a conventional blood culture as part of standard care OR * Having undergone sepsis evaluation collection of blood for a conventional blood culture as part of standard care in the past 72 hours Exclusion Criteria: * Apart from an age criterion, there are no strict exclusion criteria. However, for the analysis of the secondary outcome (I.e. the testing of diagnostic accuracy of both MC as well as conventional culture for clinical sepsis), we plan to exclude all children who ultimately have a clear alternative cause for clinical illness that does not directly result from bacteraemia or bacterial sepsis. This will remain true in the case of conventional culture positivity, either when considered a contaminant as well as when considered a contributing factor in the presence of any of the causes of clinical illness mentioned below. A potential subject who meets any of the following criteria will be excluded from participation in this study These causes include, but are not limited to: * In case of the potential inclusion of a neonate suspicious for EOS, confirmed congenital infection with TORCHES (toxoplasmosis, rubella, cytomegalovirus, syphilis and herpes) will lead to exclusion particularly for the neonatal population * Auto inflammatory disease * Hemophagocytic syndrome * SIRS (Systemic Inflammatory Response Syndrome following a severe viral infection

Contact & Investigator

Central Contact

Tim de Meij, MD, PhD

✉ t.demeij@amsterdamumc.nl

📞 +3120 566 9111

Principal Investigator

Tim de Meij, MD, PhD

PRINCIPAL INVESTIGATOR

Amsterdam UMC

Frequently Asked Questions

Who can join the NCT06018792 clinical trial?

This trial is open to participants of all sexes, aged 0 Years or older, up to 18 Years, studying Sepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06018792 currently recruiting?

Yes, NCT06018792 is actively recruiting participants. Contact the research team at t.demeij@amsterdamumc.nl for enrollment information.

Where is the NCT06018792 trial being conducted?

This trial is being conducted at Amsterdam, Netherlands, Haarlem, Netherlands.

Who is sponsoring the NCT06018792 clinical trial?

NCT06018792 is sponsored by Jip Groen. The principal investigator is Tim de Meij, MD, PhD at Amsterdam UMC. The trial plans to enroll 1,835 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology